Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech and AlgoRx Complete Enrollment for Phase 1/2 Trial of Avrina, New Drug Candidate for Eczema
Oct 27, 2005
|
74.1 KB
|
| |
SOUTH SAN FRANCISCO, Calif. and SECAUCUS, N.J., Oct 27, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) and AlgoRx Pharmaceuticals, Inc. today announced that enrollment has been completed for a multi-center Phase 1/2 clinical trial of Avrina(TM), Corgentech's NF-kappaB Decoy drug candidate for the treatment of...
|
|
|
Corgentech Announces Third Quarter 2005 Financial Results
Oct 26, 2005
|
81.5 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 26, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) today reported financial results for the third quarter and nine months ended September 30, 2005.
"On September 23, 2005, we entered into a merger agreement with AlgoRx Pharmaceuticals. The combined organization will create...
|
|
|
Corgentech to Host Webcast Analyst Meeting on Friday, October 21, 2005
Oct 19, 2005
|
64.3 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, will webcast an analyst meeting that it is hosting in New York, NY at 12 p.m. Eastern time on Friday, October 21, 2005 to discuss the combined product pipeline of Corgentech and AlgoRx Pharmaceuticals, Inc.
In...
|
|
|
AlgoRx and Corgentech Announce Positive Phase 2 Data Demonstrating New Drug Significantly Reduces Foot Pain in Patients With Morton's Neuroma
Oct 18, 2005
|
78.5 KB
|
| |
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Oct 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK) today announced positive data from a Phase 2 trial of ALGRX 4975 in patients with Morton's neuroma-a painful neuropathy of the foot. In the 58-patient randomized, double-blind, placebo-co...
|
|
|
AlgoRx and Corgentech Announce Positive Data From Phase 3 Trial of ALGRX 3268
Oct 5, 2005
|
76.8 KB
|
| |
SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Oct 05, 2005 /PRNewswire-FirstCall via COMTEX/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. (Nasdaq: CGTK) today announced positive data from the first of two ongoing Phase 3 trials of ALGRX 3268 -- a fast-acting local anesthetic administered into the skin by powder injection and aimed at redu...
|
|
|
Click here to download our most recent fact sheet.